# Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

> **NCT02206568** · PHASE1 · WITHDRAWN · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.**

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** URAL

## Key facts

- **NCT ID:** NCT02206568
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206568, "Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02206568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*